Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

BACKGROUND: Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%–4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuler, M., Berardi, R., Lim, W.-T, de Jonge, M., Bauer, T. M., Azaro, A., Gottfried, M., Han, J.-Y., Lee, D. H., Wollner, M., Hong, D. S., Vogel, A., Delmonte, A., Akimov, M., Ghebremariam, S., Cui, X., Nwana, N., Giovannini, M., Kim, T. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720758/
https://www.ncbi.nlm.nih.gov/pubmed/32240796
http://dx.doi.org/10.1016/j.annonc.2020.03.293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720758/
https://www.ncbi.nlm.nih.gov/pubmed/32240796
http://dx.doi.org/10.1016/j.annonc.2020.03.293

Ejemplares similares